What are the guidelines for hospital discharge of infants receiving phototherapy for hyperbilirubinemia?

Hospital Discharge Guidelines for Infants on Phototherapy for Hyperbilirubinemia

Discontinue phototherapy when the total serum bilirubin (TSB) has declined by 2 to 4 mg/dL below the hour-specific phototherapy threshold at which treatment was initiated, then discharge with mandatory follow-up based on specific risk stratification 1.

Criteria for Phototherapy Discontinuation

The decision to stop phototherapy and proceed with discharge requires:

• TSB measurement (not transcutaneous bilirubin) to confirm the bilirubin level has dropped 2-4 mg/dL below the original treatment threshold 1
• Individualized assessment considering:
  • The initial TSB level when phototherapy started
  • The underlying cause of hyperbilirubinemia
  • The magnitude of difference between current TSB and phototherapy threshold
  • Risk factors for rebound hyperbilirubinemia 1

Critical point: Do not rely on transcutaneous bilirubin (TcB) measurements for discharge decisions—TSB is the definitive diagnostic test that must guide all interventions 1.

Risk-Stratified Post-Discharge Follow-Up Protocol

High-Risk Infants (Mandatory Close Follow-Up)

Measure TSB at 8-12 hours after phototherapy discontinuation AND the following day if the infant has ANY of these criteria 1:

• Received phototherapy before 48 hours of age
• Gestational age <38 weeks
• Positive direct antiglobulin test (DAT)
• Suspected or confirmed hemolytic disease

Standard-Risk Infants

Measure TSB within 1-2 days after phototherapy discontinuation for all other infants who received phototherapy 1.

After 24 hours post-phototherapy: TcB becomes reliable and may be used instead of TSB for follow-up measurements 1.

Safety Considerations Before Discharge

Evaluate the Underlying Cause

Before discharge, clinicians must identify the etiology of hyperbilirubinemia 1:

• Check G6PD enzyme activity in any infant with:
  • Jaundice of unknown cause
  • TSB rising despite intensive phototherapy
  • Sudden TSB rise after initial decline
  • Required escalation of care

Monitor for Rebound Hyperbilirubinemia

The risk of rebound is real and potentially dangerous. Research shows:

• Rebound typically occurs at mean 12.5-14.1 hours after stopping phototherapy 2
• Average rebound increase: 0.83-0.86 mg/dL 2
• Infants discharged ≤5.5 mg/dL below phototherapy threshold have 7 times higher readmission risk (7.9% vs 1.2%) 3

Practical discharge margin: Maintain >5.5 mg/dL safety margin below the phototherapy threshold to minimize readmission risk 3.

Alternative to Hospital Readmission

Home phototherapy with LED-based devices is an option for infants who meet specific criteria and develop TSB above phototherapy threshold after initial discharge 1. This approach:

• Reduces conventional hospital readmissions to approximately 1% 4
• Requires specialized medical follow-up and effective phototherapy device
• Is feasible for neonates with high risk of severe hyperbilirubinemia 4

Common Pitfalls to Avoid

1. Using TcB for discharge decisions: TcB is not accurate enough for treatment decisions—always use TSB 1

2. Discharging too close to threshold: Maintaining only a narrow margin below phototherapy threshold significantly increases readmission rates 3

3. Inadequate follow-up planning: Failure to schedule appropriate post-discharge TSB measurements based on risk stratification leads to missed rebound hyperbilirubinemia 1

4. Ignoring ethnic and feeding risk factors: Asian and Hispanic infants, as well as exclusively breastfed infants, have higher bilirubin levels and readmission rates requiring closer monitoring 3

5. Premature discontinuation: Stopping phototherapy before achieving adequate TSB decline (2-4 mg/dL below threshold) increases rebound risk 1

Additional Monitoring Requirements

During the post-discharge follow-up period, additional TSB testing frequency depends on 1:

• Post-phototherapy TSB level and trajectory
• Presence of risk factors
• Rate of bilirubin rise if hemolysis suspected (≥0.3 mg/dL/hour in first 24 hours or ≥0.2 mg/dL/hour thereafter indicates possible hemolysis) 1

The 2024 AAP guidelines represent the most current evidence-based approach, emphasizing that proper discharge planning with risk-stratified follow-up prevents kernicterus while minimizing unnecessary healthcare utilization 1. Recent implementation studies confirm these guidelines reduce phototherapy use and TSB checks without increasing readmission rates when properly applied 5.